18 December 2025: Oncoinvent ASA (the “Company”) hereby calls for an extraordinary general meeting to be held on Thursday 8 January at 11:30 hours (CET) to, inter alia, resolve approval of a i) audited interim balance sheet, ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Board of Directors. The … Read more
10 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”). Further, reference is made to the stock exchange announcement published by the Company on 5 December 2025 regarding the resolution by the board of directors of the Company to issue 31,199,997 new shares in the Company, each with a nominal value of NOK 0.50, at a subscription price of NOK 0.50 per share (the “Underwriting Commission Shares”) to be delivered to the underwriters pursuant to the subscription and underwriting agreements dated 30 June 2025 as settlement of their entitlement to an underwriting fee under said agreements.
The share capital reduction to reduce the nominal value of the shares in the Company and the share capital increases pertaining to the issuance of the Offer Shares and the Underwriting Commission Shares have today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret).
The Company’s registered share capital following the share capital reduction and the share capital increases related to the issue of the Offer Shares and the Underwriting Commission Shares is NOK 223,920,562.50 divided into 447,841,125 shares, each with a nominal value of NOK 0.50.
Oslo, Norway, 8 December 2025 – Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic … Read more
8 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”). Further, … Read more
5 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
5 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
2 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. Further reference is made to the stock exchange announcement published by the Company on 2 December 2025, regarding the final result of the Rights Issue and the allocation of the new shares.
2 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
1 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
1 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.